Bempedoic Acid Significantly Reduces LDL-Cholesterol on Top of Statin Therapy: Results of the CLEAR Wisdom Trial, Published in the Journal of the American Medical Association
Daiichi Sankyo Europe GmbH (hereafter, ‘Daiichi Sankyo’) today announced the publication of results from the Phase 3 CLEAR Wisdom trial in the Journal of the American Medical Association (JAMA).1 Bempedoic acid is currently undergoing review for marketing authorisation by the European Medicines Agency (EMA) and by the United States Food and Drug Administration (FDA).
CLEAR Wisdom, a Phase 3, double-blind, randomised trial, evaluated the efficacy, long-term safety and tolerability of bempedoic acid 180 mg versus placebo in 779 patients with atherosclerotic cardiovascular disease (ASCVD) and/or heterozygous familial hypercholesterolaemia (HeFH) inadequately controlled with current lipid-modifying therapies, added on to maximally-tolerated statin therapy, which may mean no statin at all.1
The JAMA publication includes results for the primary efficacy endpoint of low-density lipoprotein cholesterol (LDL-C) lowering at 12 weeks and key secondary endpoints of safety and tolerability over 52 weeks. The publication reports that bempedoic acid:1
- significantly lowered LDL-C by 17% on background maximally-tolerated statin therapy at 12 weeks, with nearly all patients (85%, 444/522 ) on moderate- or high-intensity statins, and the effect was durable through 52 weeks;
- significantly lowered high-sensitivity C-reactive protein (hsCRP), an important marker of the underlying inflammation associated with cardiovascular disease, by 19%, and the effect was durable through 52 weeks;
- showed no worsening of haemoglobin A1c (HbA1c) (- 0.21% vs. placebo) in patients with diabetes at 12 weeks;
- showed overall adverse event rates comparable with placebo (bempedoic acid 70% 366/522 vs. placebo 71% 182/257) at 52 weeks, and the proportion of patients with reported serious adverse events was similar compared with placebo (bempedoic acid 20% 106/522 vs. placebo 19% 48/257) at 52 weeks;
- showed adjudicated three-component major adverse cardiac event rates of 2.7% (14/522) with bempedoic acid and 4.7% (12/257) with placebo.
“The CLEAR Wisdom trial demonstrated that bempedoic acid provided additional LDL-C lowering in patients on background maximally-tolerated statin therapy and had an overall adverse event profile that was comparable to placebo,” said Anne C. Goldberg MD, FACP, FAHA, FNLA, Professor of Medicine, Division of Endocrinology, Metabolism and Lipid Research at Washington University, St. Louis and lead study author. “These results are consistent with the results reported from the largest long-term Phase 3 study of bempedoic acid, Study 1 or CLEAR Harmony, which were published earlier this year in the New England Journal of Medicine. Results across the Phase 3 development programme show that bempedoic acid has the potential to be a treatment option for high-risk patients who require additional LDL-C lowering.”
“We believe that bempedoic acid will address an important unmet need for patients who require additional LDL-C lowering and are not reaching their goals with existing oral lipid lowering therapies,” said Wolfgang Zierhut, MD, Head of Antithrombotic and Cardiovascular Medical Affairs Department at Daiichi Sankyo Europe. “Many patients remain at high risk of a cardiovascular event and need additional treatment options to achieve LDL-C goals. This is even more pertinent given that the latest guidelines suggest even lower LDL-C goals to provide optimal protection.”
- ENDS -
Design of Global Pivotal Phase 3 Study 2 (1002-047, also known as CLEAR Wisdom)
The 52-week, global, pivotal Phase 3 randomised, double-blind, placebo-controlled, multi-centre study evaluated the efficacy and safety of bempedoic acid 180 mg/day versus placebo. The study was conducted at 86 sites in North America and Europe. A total of 779 patients were randomised 2:1 to receive bempedoic acid or placebo. The primary efficacy objective was to assess the 12-week LDL-C lowering efficacy of bempedoic acid versus placebo. Secondary objectives included evaluating the safety and tolerability of bempedoic acid versus placebo, the 24-week and 52-week LDL-C lowering efficacy of bempedoic acid versus placebo, and bempedoic acid’s effects on other risk markers after 12 weeks of treatment, including hsCRP and HbA1c, versus placebo.
With a targeted mechanism of action, bempedoic acid is an oral, once-daily ATP Citrate Lyase (ACL) inhibitor that reduces cholesterol synthesis in the liver and thereby lowers circulating LDL-C levels.2,3 It is intended for patients with hypercholesterolaemia and/or at high risk of atherosclerotic cardiovascular disease (ASCVD) who need additional LDL-C lowering despite maximally-tolerated statin therapy.
Bempedoic acid has a unique, innovative mode of action, which is complimentary to other lipid-lowering therapies, such as statins.4 Due to its liver-specific mode of action, bempedoic acid has a reduced potential to induce the muscle-related side-effects commonly associated with statin therapy and provide additional LDL-C lowering on top of statin monotherapy in clinical trials.3
Bempedoic acid (180 mg) and the bempedoic acid / ezetimibe fixed dose combination tablet (180 mg/10 mg) are currently under review by the European Medicine Agency’s (EMA) Committee for Medicinal Products for Human Use and the U.S. Food and Drug Administration for LDL-C lowering in patients who are not yet at their target LDL-C level. Daiichi Sankyo Europe licensed exclusive commercialisation rights to these products in the European Economic Area and Switzerland from Esperion. Approval decisions are expected during the first half of 2020.
About Daiichi Sankyo
Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical therapies to improve standards of care and address diversified, unmet medical needs of people globally by leveraging our world-class science and technology. With more than 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 15,000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people. In addition to a strong portfolio of medicines for cardiovascular diseases, under the Group’s 2025 Vision to become a “Global Pharma Innovator with Competitive Advantage in Oncology,” Daiichi Sankyo is primarily focused on providing novel therapies in oncology, as well as other research areas centred around rare diseases and immune disorders. For more information, please visit: www.daiichisankyo.com.
1 Goldberg AC, et al. Effect of Bempedoic Acid vs Placebo Added to Maximally Tolerated Statins on Low-Density Lipoprotein Cholesterol in Patients at High Risk for Cardiovascular Disease. The CLEAR Wisdom Randomized Clinical Trial. JAMA. 2019;322(18):1780-1788. doi:10.1001/jama.2019.16585.
2 Ray KK, et al. Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol. N Engl J Med. 2019;380:1022–32.
3 Ballantyne CM, et al. Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: A randomized, placebo-controlled study. Atherosclerosis.2018;277:195–203.
4 Laufs U, et al. Efficacy and Safety of Bempedoic Acid in Patients with Hypercholesterolemia and Statin Intolerance. J Am Heart Assoc. 2019;8(7):e011662.
Lydia Worms (Europe)
Daiichi Sankyo Europe GmbH
Communications & Product PR Europe
+49 (89) 7808751
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Seoul Semiconductor’s SunLike Series Natural Spectrum LEDs Adopted by Italian Designed Architectural Lighting Brand for Motorized Luminaire with Smart Wireless Controls13.12.2019 09:00:00 CET | Press release
Seoul Semiconductor Co., Ltd. (KOSDAQ 046890), a leading global innovator of LED technology, announced that it has achieved smart lighting design with SunLike Series natural spectrum LEDs in cooperation with Casambi Technologies Oy (“Casambi”), a leading developer of wireless lighting control systems based on Bluetooth Low Energy (BLE), and it has been adopted for the Italian designed architectural lighting brand formalighting Ltd. (“formalighting”), a global manufacturer of Italian designed architectural lighting systems and solutions for a new product line which offers motorized luminaire with smart wireless controls. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191213005009/en/ SunLike implemented in motion lamps (Photo: Business Wire) The SunLike COB LED packages have been adopted by formalighting for the new fixtures, Moto-Zero 40 Compasso and Moto-Zero 66 Zoom, in track mounted motorized spotlight range. In this sect
Amazon Studios Orders Fourth Season of the Award-Winning Comedy The Marvelous Mrs. Maisel12.12.2019 23:10:00 CET | Press release
(NASDAQ:AMZN) – Amazon Studios announced today that it has ordered a fourth season of the Emmy and Golden Globe-Award winning comedy The Marvelous Mrs. Maisel. The third season premiered Friday, Dec. 6 on Amazon Prime Video in more than 200 countries and territories worldwide. The Marvelous Mrs. Maisel received two Golden Globe nominations this week, for Best Television Series, Musical or Comedy, and for star Rachel Brosnahan for Best Performance by an Actress in a Series, Musical or Comedy. “We were thrilled to hear that for the fourth time, we do not have to pack up and vacate the premises,” said Creator and Executive Producer Amy Sherman-Palladino and Executive Producer Daniel Palladino. “We’d like to thank Amazon for all their faith and support, their partnership and enthusiasm, and for letting us hang with our favorite people, the cast and crew of Maisel, for a little while longer.” “The Marvelous Mrs. Maisel has been a worldwide phenomenon, and Season 3 has been no exception, wit
“The ABCs of SMBs” – AGC’s Latest Insight Report on the $380B SMB Software & Services Market12.12.2019 19:25:00 CET | Press release
AGC Partners is pleased to announce the release of its latest industry thought piece – “The ABCs of SMBs.” This piece explores the market for software and services selling into small and midsize businesses (SMB) globally, and the technology providers and strategies used to best penetrate this underserved and rapidly growing market. The low-cost ease of use SaaS delivery model has broken open the SMB market, generating $380 billion in software spend. AGC Partners is now finishing its 17th year of business with record revenues, profits, and deals closed. We have built the leading global tech boutique focused on the mid- and micro-cap M&A and growth financing markets. AGC Partners is the SaaS deal leader, with 98 closed deals and 387 total completed transactions. We have built a high-powered team of tech banking specialists, with 20 partners across 10 offices, including London, New York, Boston, and San Francisco. SMB is a different animal than the large enterprise market, and requires a
Mary Kay Advances Commitment to Global Female Empowerment at United Nations Global Compact Gender Equality Forum12.12.2019 16:40:00 CET | Press release
In its ongoing commitment to female empowerment and entrepreneurship, Mary Kay Inc., alongside Warner Bros., Qualcomm and more, recently addressed the economic, social and sustainability benefits of global gender equality at the United Nations Global Compact for Gender Equality, an event organized by Global Compact Network USA (GCNUSA) in Los Angeles, California. The regional event took place at the Metro Headquarters at One Gateway Plaza and invited attendees to explore the many ways in which businesses can take action on the United Nations Sustainable Development Goal 5 (SDG 5) to promote gender equality in the workplace, marketplace, and community. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191212005594/en/ Deborah Gibbins, COO at Mary Kay with Sandeep Khagram, Director General and Dean, Thunderbird School of Global Management, Arizona State University (Photo: Mary Kay Inc.) Endorsed by chief executives, the Global Co
Andersen Global Strengthens Presence in Nigeria with The New Practice12.12.2019 14:30:00 CET | Press release
Andersen Global entered into a Collaboration Agreement with Lagos-based law firm, The New Practice (TNP), increasing the global organization’s footprint in Africa and strengthening its presence in Nigeria. Founded in 2007, TNP’s practice includes Office Managing Partner Baba Alokolaro and more than 20 legal professionals. The firm provides a large range of commercially oriented legal services in a number of disciplines including capital markets, commercial dispute resolution, corporate finance, infrastructure, construction, real estate, energy and natural resources, corporate, commercial, mergers and acquisitions, private equity, FinTech, technology, e-commerce and business advisory. “We are driven by the firm belief in doing things better and exploring new ways to deliver results and solutions to our clients, which is why we feel so strongly about our collaboration with Andersen Global,” Baba said. “This is an opportunity for us to strengthen our service offerings and expand our globa
Luxembourg's Acceleration Programme Fit 4 Start Call for ICT and Space Tech Applications Open12.12.2019 14:26:00 CET | Press release
Fit 4 Start is Luxembourg’s acceleration programme for supporting start-ups. Start-ups benefitting from the programme, established in Luxembourg or another country, including outside the European Union, are selected twice a year. Launched by the Ministry of the Economy and managed by Luxinnovation, the Fit 4 Start programme has opened its next call for candidates for national and international start-ups. The next edition of Fit 4 Start is aimed at young innovative companies active in the information and communication technologies sector (ICT) as well as the space technology sector. Registrations can be made online up until 20 January 2020 at 12.00 hours (midday Luxembourg time) via www.fit4start.com. A pre-selection is carried out on the basis of the applications received. Candidates who are pre-selected will be notified on 3 February 2020. The pre-selected start-ups then meet for a ‘pitching’ session organised during the ‘Pitching and Graduation day’ which will take place on 26 March